CAR T-cell therapy ‘highly effective’ in high-risk CLL

Cameron Turtle, MBBS, PhD
Photo by Robert Hood,
Fred Hutchinson Cancer
Research Center
A chimeric antigen receptor (CAR) T-cell therapy is “highly effective” in high-risk patients with chronic lymphocytic leukemia (CLL), according to researchers. The CD19 CAR T-cell therapy, JCAR014, produced an overall response rate of 71% and a complete response (CR) rate of 17% in a phase 1/2 trial of patients with relapsed/refractory CLL. Eighty-three percent of patients experienced cytokine release syndrome (CRS), and 33% developed neurotoxicity. One patient died of CRS/neurotoxicity. Researchers reported these results in The Journal of Clinical Oncology. [Read Article]

Death is most frequent major adverse outcome after VTE

Patient takes anticoagulant
after knee surgery
Photo courtesy of
Boehringer Ingelheim
Data from the GARFIELD-VTE registry showed that, in the first 6 months after a patient was diagnosed with venous thromboembolism (VTE), death was the most frequent major adverse outcome. More than half of the deaths were related to cancer, with small percentages of patients dying from VTE complications and bleeding events. GARFIELD-VTE is a prospective registry designed to provide insight into the management of VTE in everyday clinical practice. [Read Article]

Combo may be option for elderly patients with untreated AML

Andrew Wei, MBBS, PhD
The combination of venetoclax and low-dose cytarabine (VEN+LDAC) appears to be a feasible treatment option for elderly patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. In a phase 1/2 study of such patients, VEN+LDAC was considered well-tolerated, conferring moderate myelosuppression and largely low-grade non-hematologic toxicities. In addition, the combination produced “rapid and durable” responses, and early death rates were low, according to Andrew H. Wei, MBBS, PhD, of Monash University in Melbourne, Victoria, Australia. [Read Article]